Irinotecan with ramucirumab did not provide a significant OS advantage over irinotecan monotherapy.
Esophageal
Advertisement
Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
The panel concludes with a discussion on treatment strategies for metastatic esophageal squamous cell carcinoma.
The panel shifts focus to the 1L treatment of metastatic gastroesophageal cancers, exploring biomarker testing strategies.
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.